Imaging Biometrics, a wholly owned subsidiary of IQ-AI, is highlighting results from a recent glioma study published in Neuroradiology.
The study, led by Siem Herings, from Radboud University Medical Center in Nijmegen, the Netherlands -- Herings is a member of the lab of Dylan Henssen, MD, PhD -- validates the benefit of the company's IB Rad Tech workflow software for distinguishing treatment effect from tumor progression in post-treatment glioma patients.
The research included 50 glioma patients and showed that the approach "effectively differentiates between treatment-related abnormalities and tumor progression," the company said in a statement.
"This distinction is critical for determining the appropriate treatment course for patients following surgery and chemo-radiotherapy," it noted.
